Favipiravir, umifenovir and camostat mesylate: a comparative study against SARS-CoV-2
Unal, M. A.; Besbinar, O.; Nazir, H.; Summak, G. Y.; Bayrakdar, F.; Delogu, L. G.; Taskin, T.; Ozkan, S. A.; Akcali, K. C.; Yilmazer, A.
Show abstract
Since the first cases the coronavirus disease caused by SARS-CoV-2 (COVID-19) reported in December 2019, worldwide continuous efforts have been placed both for the prevention and treatment of this infectious disease. As new variants of the virus emerge, the need for an effective antiviral treatment continues. The concept of preventing SARS-CoV-2 on both pre-entry and post-entry stages has not been much studied. Therefore, we compared the antiviral activities of three antiviral drugs which have been currently used in the clinic. In silico docking analyses and in vitro viral infection in Vero E6 cells were performed to delineate their antiviral effectivity when used alone or in combination. Both in silico and in vitro results suggest that the combinatorial treatment by favipiravir and umifenovir or camostat mesylate has more antiviral activity against SARS-CoV-2 rather than single drug treatment. These results suggest that inhibiting both viral entry and viral replication at the same time is much more effective for the antiviral treatment of SARS-CoV-2.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 96%
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 95%
- Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro 95%
Similar papers in this journal
- Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors 97%
- Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron variants 96%
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 95%
Similar papers in this journal
- Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell 95%
- Effects of SARS-CoV-2 Mutations on Protein Structures and Intraviral Protein-Protein Interactions 94%
- Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein 94%
Similar papers in this journal
- Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo 95%
- Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods 95%
- Discovery of Potent Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.